Kestra Medical Technologies Ltd (KMTS)

NASD · Healthcare · Medical Instruments & Supplies · USA

Kestra Medical Technologies Ltd is a small cap company (market value between $300 million and $2 billion) in the Medical Instruments & Supplies industry.

Kestra Medical Technologies develops and sells the ASSURE Wearable Cardioverter Defibrillator, a portable device that monitors heart rhythms and automatically administers therapy to patients at risk of sudden cardiac arrest. The company offers an integrated platform combining the device with digital tools and clinical support services to engage patients and assist healthcare providers in managing cardiac recovery.

From its FY2026 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Kestra Medical Technologies Ltd stock.

Our verdict on KMTS

Not valued: We cannot value this company yet.

We do not publish a value for this company: its filings cover three fiscal years and projecting growth needs four in a row.

ETFs with the most weight in KMTS

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Medical Instruments & Supplies

All 52 Medical Instruments & Supplies stocks

Cheaper than KMTS in Medical Instruments & Supplies

23 more in this industry show a wider margin of safety.

Is KMTS undervalued or overvalued?

We do not publish a verdict on KMTS yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.

What is the intrinsic value of KMTS?

We do not publish one (as of the 2026-11-17 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.